Among the results of a new study by healthtech B-corp Radicle Science, participants experienced a 71% improvement in their well-being on average.

Thirteen U.S. brands were included in the four-week Radicle Advancing CBD Education and Science (ACES) study, which set out to determine whether botanical products with CBD deliver therapeutic benefits across five health outcomes, including well-being, quality of life, longer-term pain, feelings of anxiety and sleep quality.

Initial findings show that a significant number of participants experienced “clinically meaningful” improvements, meaning they realized distinct and palpable improvements in quality of life through improvements in the respective health outcomes studied. Notably, across all health outcomes, the largest improvements were observed within the first week.

Other key findings include a clinically meaningful improvement in anxiety among 63% of participants; 61% experienced a clinically meaningful improvement in sleep quality; 47% experienced a clinically meaningful improvement in pain; and 61% reported an effect within one to four hours of taking their product.

Radicle ACES gathered real-world health outcomes from a diverse population of the nearly 3,000 participants across a variety of ethnicities, age groups, geographies, behavioral habits and pre-existing health conditions. The Radicle approach eliminates all physical infrastructure and instead collects data directly from participants as they go about their day-to-day life, in their real world environment. A full report of the anonymized, aggregate findings will be released in early 2022.

Ultimately, the B-corp’s mission is to create “the new standard of trust and transparency consumers deserve and healthcare providers demand on these widely accessible potential therapies.” That’s good news for consumers and retailers alike.